Notably, PTEN has been reported to be frequently mutated in human cancers and is a well‐known anti‐oncogene that encodes a dual‐specificity phosphatase antagonizing the phosphatidylinositol 3‐kinase (PI3K) class I/AKT/mTOR pathway.31 Here, MTOR is linked to cancer.